Applied Therapeutics Förvaltning

Förvaltning kriterier kontrolleras 2/4

Applied Therapeutics VD är Les Funtleyder, utsedd i Nov 2023, har en anställningstid på 1.33 år. äger direkt 0.12% av företagets aktier, värda $ 72.97K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 1.3 år respektive 5.9 år.

Viktig information

Les Funtleyder

Verkställande direktör

US$675.2k

Total ersättning

VD-lön i procent	n/a
Anställning som VD	1.3yrs
Ägande av VD	0.1%
Ledningens genomsnittliga anställningstid	1.3yrs
Styrelsens genomsnittliga mandatperiod	5.9yrs

Senaste uppdateringar av ledningen

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24

VD OCH KONCERNCHEF

Les Funtleyder (54 yo)

1.3yrs

Anställning

US$675,150

Kompensation

Mr. Les D. Funtleyder served as Interm CEO, CFO, Principal Financial Officer & Independent Director of Applied Therapeutics, Inc. from December 20, 2024. He was CFO, Principal Financial Officer & Independe...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Les Funtleyder	Interm CEO	1.3yrs	US$675.15k	0.12% $ 73.0k
Riccardo Perfetti	Chief Medical Officer	6.6yrs	US$3.04m	0.24% $ 140.1k
John Johnson	Executive Chairman	less than a year	inga uppgifter	inga uppgifter
Constantine Chinoporos	COO & Chief Business Officer	1.3yrs	inga uppgifter	0.23% $ 139.0k
Catherine Thorpe	Chief Accounting Officer	1.8yrs	inga uppgifter	inga uppgifter
Corwin Hooks	Chief Commercial Officer	less than a year	inga uppgifter	inga uppgifter
Reena Colacot	Head of Quality	less than a year	inga uppgifter	inga uppgifter

1.3yrs

Genomsnittlig anställningstid

59yo

Genomsnittlig ålder

Erfaren ledning: APLT s ledningsgrupp anses inte vara erfaren ( 1.3 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Les Funtleyder	Interm CEO	8.8yrs	US$675.15k	0.12% $ 73.0k
John Johnson	Executive Chairman	less than a year	inga uppgifter	inga uppgifter
Jay Skyler	Independent Director	5.9yrs	US$92.53k	0.017% $ 10.2k
Lawrence Steinman	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Teena Lerner	Lead Independent Director	8yrs	US$88.78k	0.052% $ 30.9k
Stacy Kanter	Independent Director	5.8yrs	US$94.40k	0.054% $ 32.3k
Gregg Stone	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Donald Landry	Chairman of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Donald D'Amico	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Roy Freeman	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Roxana Mehran	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter

5.9yrs

Genomsnittlig anställningstid

67yo

Genomsnittlig ålder

Erfaren styrelse: APLT s styrelse anses vara erfaren ( 5.9 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/11 02:08
Aktiekurs vid dagens slut	2025/03/11 00:00
Intäkter	2024/09/30
Årlig intjäning	2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Applied Therapeutics, Inc. bevakas av 11 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Brian Skorney	Baird
Carter Gould	Barclays
Catherine Seifert	CFRA Equity Research

Applied Therapeutics Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Applied Therapeutics, Inc. Appoints Reena Thomas Colacot as Head of Quality

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Chair of the Board of Directors recently sold US$1.7m worth of stock

Recent updates

Applied Therapeutics Receives Written Notification from Nasdaq Regarding Bid Price Requirement

Applied Therapeutics Receives Written Notification from Nasdaq Regarding Bid Price Requirement

Applied Therapeutics, Inc. Appoints Reena Thomas Colacot as Head of Quality

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Robbins Geller Rudman & Dowd LLP Announces That Applied Therapeutics, Inc. Investors with Substantial Losses Has Opportunity to Lead the Applied Therapeutics Class Action Lawsuit

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

Applied Therapeutics: Pushing Towards FDA Approval

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$13.63

Price target decreased to US$28.80

Applied Therapeutics, Inc. Announces Executive Changes

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Price target increased to US$39.20

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Applied Therapeutics, Inc Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Price target decreased to US$34.40

Price target increased to US$49.40

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Chair of the Board of Directors recently bought US$145k worth of stock

Chief Medical Officer notifies of intention to sell stock

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Chief Medical Officer exercised options and sold US$714k worth of stock

Chief Medical Officer exercised options and sold US$97k worth of stock

Price target decreased to US$44.50